Full-Time

Senior Scientist II

Computational Discovery Science

Updated on 3/13/2025

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

Compensation Overview

$130k - $175kAnnually

+ Incentive Compensation + Restricted Stock Units

Senior

Company Historically Provides H1B Sponsorship

Chicago, IL, USA

This is a hybrid position, which may require some in-office days.

Category
Computational Biology
Genomics
Public Health
Biology & Biotech
Required Skills
Python
R
SQL
Requirements
  • PhD degree in a quantitative discipline (e.g., Biostatistics/Statistical Genetics, Bioinformatics, Computational Biology, Computational Immunology, or similar) plus 2 years of experience or postdoctoral studies
  • Alternatively, a PhD in Molecular Biology or another Life Science degree combined with a very strong record of computational biology
  • Minimum 2+ years in drug development leveraging genomic and clinical/real-world data for drug discovery and development
  • Proficient in R, Python, and SQL
  • Strong understanding of cancer biology
  • Excellent written and verbal communication skills, with the ability to present complex information clearly and persuasively to diverse audiences
Responsibilities
  • Partner with our pharma clients to design, develop, and execute computational target discovery research projects leveraging the Tempus platform to advance precision medicine research programs
  • Develop and implement scientific strategies and experimental work plans, including identifying new methodologies and approaches for large clinico-genomic databases and PDOs
  • Integrate the above to prioritize target opportunities matched to biomarker and indication strategies that enhance the likelihood of developmental success
  • Evaluate clinical trial design by testing assumptions, refining eligibility criteria, and characterizing patient outcomes on standard of care
  • Develop novel biomarkers of response signatures
  • Independently execute complex translational or real-world evidence research projects integrating molecular and clinical data from Tempus’ multimodal data platform to derive real-world insights for biopharma partners
  • Expert in navigating client interactions; present scientific findings clearly and meaningfully to diverse sets of external stakeholders
  • Document, summarize, and communicate highly technical results and methods clearly to non-technical audiences
  • Author abstracts, posters, and peer-reviewed publications to illustrate the value of multimodal analysis and AI in drug discovery in coordination with our partners or internal R&D teams
  • Become an expert in our biopharma partners’ strategy, pipeline, and portfolio to proactively determine all areas that the Tempus platform could add value to the drug development process of our partners
  • Stay current with industry trends, best practices, and advancements in computational oncology research. Apply this knowledge to enhance research methodologies and improve overall research quality on the team.
Desired Qualifications
  • Strong understanding of statistical methods, molecular data, and machine learning in drug discovery with experience in integrative modeling of multi-modal clinical and omics data
  • Previous experience working with large transcriptome and NGS data sets
  • Prior consulting and/or client-facing experience is highly desirable
  • Ability to work collaboratively in a team environment
  • Thrive in a fast-paced environment and willing to shift priorities seamlessly
  • Experience with R package development
  • Strong peer-reviewed publication record
  • Experience with: Pandas, NumPy, SciPy, Scikit-learn, Jupyter Notebooks, RStudio, tidyverse, ggplot, Git, matplotlib, seaborn
  • Goal orientation, self-motivation, and drive to make a positive impact in healthcare

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Additionally, Tempus conducts research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus secured $560 million in debt financing to support growth and acquisitions.
  • Partnerships with Stemline and Artera expand Tempus' AI platform applications.
  • The launch of the Olivia app empowers patients with AI-driven health management.

What critics are saying

  • High debt levels may strain Tempus' financial stability if revenue targets aren't met.
  • Increased competition from AI healthcare platforms could erode Tempus' market share.
  • Regulatory challenges in AI and data privacy could impact Tempus' operations.

What makes Tempus unique

  • Tempus uses AI to provide personalized treatment insights for cancer patients.
  • Their platform integrates clinical and molecular data for precision medicine.
  • Tempus' AI-driven liquid biopsy assay enhances cancer detection and profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Business Wire
Feb 25th, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million

Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.

Pulse 2.0
Feb 24th, 2025
Tempus Secures $560M Debt Financing

Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.

Hit Consultant
Feb 21st, 2025
Stemline Therapeutics To Deploy Tempus Next’S Ai-Enabled Care Pathway Intelligence Platform

Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression

ETF Daily News
Feb 15th, 2025
Apollon Wealth Management LLC Makes New $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).

Money Morning
Feb 14th, 2025
Nancy Pelosi's Favorite AI Stock Rising Again After 13% Surge

Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.